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licenseNeutrophil gelatinase-associated lipocalin: Still a good predictive
marker of acute kidney injury in severe septic patients?Serum creatinine (sCr) is considered a lagging indicator of
acute kidney injury (AKI), and reliance on sCr as a marker for
AKI may delay initiation of appropriate therapy. Novel bio-
markers including plasma or urine keratinocyte-derived che-
mokine/Gro-a, plasma or urine neutrophil gelatinase-
associated lipocalin (NGAL), urine kidney injury molecule-
1, and urine cytokines interleukin-6 (IL-6), IL-8, and IL-18
have been investigated as early markers of AKI prior to ele-
vation of sCr.1e6 Mishra et al3 demonstrated that both plasma
and urine NGAL concentration 2 hours after surgery are
powerful independent predictors of AKI within 72 hours in
children undergoing cardiopulmonary bypass. However, serum
NGAL has been shown to increase in response to acute
infections, pancreatitis, heart failure, systemic inflammatory
syndrome, severe sepsis, and septic shock.7e10 It means
NGAL may be less specific to predict AKI under these cir-
cumstances. Using NGAL as an early marker of AKI in
intensive care patients showed heterogeneous results in several
studies.9,11e13 De Geus et al11 reported serum NGAL meas-
ured at intensive care unit (ICU) admission is not superior to
sCr-derived estimated glomerular filtration rate in predicting
the development of severe AKI in 632 adult critically ill
patients, but serum NGAL adds significant accuracy in com-
bination with estimated glomerular filtration rate. Martensson
et al9 also demonstrated that plasma NGAL is a poor predictor
for AKI in 45 septic shock patients because peak plasma
NGAL is not significantly different between septic shock
patients with and without AKI. On the contrary, Cruz et al12
found good correlation between the peak plasma NGAL
concentration with AKI severity, and that plasma NGAL was
also an early marker to predict AKI development within the
next 48 hours and the necessity of renal replacement therapy
in ICU patients. Constantin et al13 showed high sensitivity and
specificity (82% and 97%) to predict AKI by using plasma
NGAL higher than a cutoff value of 155 nmol/L. Since these
studies found plasma NGAL could predict the need for renal
replacement therapy, NGAL could be still regarded as an early
marker of severe AKI in ICU patients.11e13 However, plasma
NGAL poorly predicted mortality in the studied groups.11,12
Recently, Huang et al14 investigated the utilization of the
traditional biomarker sCr in comparison with novelx.doi.org/10.1016/j.jcma.2016.02.005
901/Copyright © 2016, the Chinese Medical Association. Published by El
(http://creativecommons.org/licenses/by-nc-nd/4.0/).biomarkers, including plasma NGAL, IL-6, and IL-10 within
24 hours after admission, to predict the development of AKI
within 7 days among severe septic patients in ICU. When the
cutoff values of sCr > 1.5 mg/dL and plasma NGAL > 150 ng/
mL were used, the study showed better predictive value of
AKI by sCr than by plasma NGAL. In comparison with the
previously mentioned studies that enrolled patients without
pre-existing chronic kidney disease and excluded patients with
admission due to AKI, the enrollment criteria of this study
include nine patients with end-stage renal disease and possibly
some patients with chronic kidney disease among the eight
patients without previous data of sCr. In addition, the values of
mean and standard deviation of plasma NGAL of patient with
Risk, Injury, Failure, Loss of kidney function, and End-stage
kidney disease (RIFLE)-failure are 217.2 ng/mL and16.8 ng/
mL, respectively, which means >97.5% of patients in this
group had a value of plasma NGAL > 183.6 ng/mL
(217.216.8 2¼ 183.6), thus, almost all patients in this
group have plasma NGAL > 150 ng/mL. This indicates that a
cutoff value of 150 ng/mL for NGAL is too low to have good
specificity for the prediction of development of RIFLE-failure
in the study patients. Furthermore, they used impaired renal
function of sCr > 1.5 mg/dL as an early marker of AKI within
7 days after ICU admission in the current study. It may lead to
potential bias if there is a lagging period between arrival at the
emergency department and admission to the ICU, and some
AKI episodes developed even several days before visiting the
hospital. The study selected an observation period of 7 days
after admission to the ICU, but the development of AKI may
appear 7 days after NGAL sampling and result in lower sen-
sitivity of plasma NGAL in predicting an acute renal insult.
Cruz et al12 also had shown decline in the area under receiver
operating characteristic curve with longer observation period.
Furthermore, most patients in the study had higher plasma
NGAL concentration owing to underlying severe sepsis, and it
contributed to lower specificity of plasma NGAL in predicting
development of AKI due to a lower cutoff value of plasma
NGAL.
Indeed, we usually do not know the exact onset of AKI in
severely septic patients, and thus it is difficult to define a
proposed time of NGAL measurement in these patients. Thesevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
412 Editorial / Journal of the Chinese Medical Association 79 (2016) 411e412superiority of plasma NGAL as an early biomarker of AKI
may be restricted to the cases with known timing of renal
insult, such as major surgical procedures, cardiopulmonary
bypass, or sudden onset of shock or sepsis during hospital-
ization. Therefore, it should be sampled as early as possible
after the patient’s arrival at medical facilities. A higher cutoff
value of plasma NGAL concentration and repeated measure-
ment may reasonably increase the predictive value of plasma
NGAL for AKI, allowing appropriate treatment as early as
possible for AKI patients in the ICU.
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